- R&I-1430
- February 2024
- 217
- PPT, PDF, WORD, EXCEL
- Healthcare & Life Sciences
address
1820 Avenue M, Brooklyn, NY, 11230, United States
mail address
sales@reportsandinsights.comContact no.
Market Overview:
"The prurigo nodularis treatment market size reached US$ 690.1 million in 2023. Looking forward, Reports and Insights expects the market to reach US$ 908.3 million in 2032, exhibiting a growth rate (CAGR) of 3.1% during 2024-2032."
|
Report Attributes |
Details |
|
Base Year |
2023 |
|
Forecast Years |
2024-2032 |
|
Historical Years |
2021-2023 |
|
Market Growth Rate (2024-2032) |
3.1% |
Prurigo nodularis is a persistent skin condition marked by itchy nodules or bumps, prompting frequent scratching. Treatment usually involves a multifaceted approach to alleviate itching, reduce inflammation, and foster skin healing. This often includes topical corticosteroids, antihistamines, phototherapy, and, in certain instances, oral medications like immunosuppressants or antidepressants. Stress management and avoidance of triggers that exacerbate itching are also key aspects of managing the condition.
The market for Prurigo Nodularis treatment offers a variety of therapeutic options to alleviate symptoms and enhance patients' quality of life. These include topical corticosteroids, antihistamines, and emollients to manage itching and inflammation. In more severe cases, systemic therapies such as oral corticosteroids, immunosuppressants, and biologic agents may be prescribed. There is also a growing interest in novel treatments, including targeted therapies and interventions that aim to modulate specific pathways involved in the condition's development. Overall, the market is driven by the demand for safe and effective treatments, emphasizing the importance of ongoing research and development efforts in this area.
Prurigo Nodularis Treatment Market Trends and Drivers:
The prurigo nodularis treatment market is fueled by several factors, including the increasing prevalence of the condition, which is driving demand for more effective therapies. Additionally, growing awareness among healthcare providers and patients about treatment options is boosting market growth. Technological advancements, especially in the development of novel therapies like biologic agents and targeted treatments, are also significant drivers. Furthermore, the market is evolving towards patient-centric approaches and personalized medicine, leading to the development of more tailored treatment options. In summary, the prurigo nodularis treatment market is undergoing significant growth and transformation, driven by medical advancements and changing patient needs.
The prurigo nodularis treatment market growth is influenced by several factors which include a rise in the global prevalence of prurigo nodularis, which is increasing demand for treatment. There is also an increase in awareness about the condition among healthcare providers and patients, leading to earlier detection and treatment. Additionally, the market is benefitting from the development of new therapies and drugs, as well as advancements in diagnostic and monitoring technologies. Collaborations between pharmaceutical firms and research institutions are also driving market expansion.
Prurigo Nodularis Treatment Market Restraining Factors:
Several factors restrain the prurigo nodularis treatment market, including limited understanding of the condition's root causes, which hampers the development of targeted therapies. The absence of standardized diagnostic criteria and the variability in disease presentation pose challenges for clinicians in both diagnosing and treating prurigo nodularis. Additionally, the high cost of certain treatments, such as biologic agents, may restrict access for some patients. Regulatory hurdles and the lengthy, expensive drug development process also impede the introduction of new therapies to the market. Together, these constraints contribute to the difficulties in effectively managing Prurigo Nodularis and advancing treatment options.
Prurigo Nodularis Treatment Market Opportunities:
Opportunities abound in the prurigo nodularis treatment market, driven by the potential for innovative therapies to meet the significant unmet medical needs in this space, given the condition's chronic nature and the limited treatment options currently available. Moreover, there is a promising opportunity for market growth in emerging economies, where prurigo nodularis may be more prevalent than reported or diagnosed. The growing emphasis on personalized medicine and targeted therapies also offers a chance for the development of more efficacious and individualized treatments for patients with prurigo nodularis.
Prurigo Nodularis Treatment Market Segmentation:
By Product:
- Antihistamines
- Capsaicin Cream
- Corticosteroids
- Emollients
- Others
In prurigo nodularis treatment, corticosteroids are a dominating as product segment due to their effectiveness in reducing inflammation and itching associated with the condition. They are commonly prescribed as a first-line treatment, providing symptomatic relief and improving the appearance of skin lesions. Although antihistamines, capsaicin cream, and emollients also play significant roles in symptom management, corticosteroids are a key component in the overall treatment regimen for Prurigo Nodularis.
By Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Retail pharmacies dominate the distribution of Prurigo Nodularis treatments, mainly due to their convenience and accessibility for patients. These pharmacies are typically located in community settings, making them easily reachable. They stock a wide range of medications and products used to treat Prurigo Nodularis, including topical corticosteroids and antihistamines. Pharmacists at retail pharmacies can also provide guidance on the proper use of these treatments. While hospital pharmacies are also important, particularly for inpatient care, many Prurigo Nodularis patients prefer the convenience and accessibility of retail pharmacies. Online pharmacies are growing in popularity but have not yet surpassed retail pharmacies, as some patients value the face-to-face interactions and advice they receive from retail pharmacists.
By Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Russia
- Poland
- Benelux
- Nordic
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- ASEAN
- Australia & New Zealand
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- Saudi Arabia
- South Africa
- United Arab Emirates
- Israel
- Rest of MEA
North America leads the prurigo nodularis treatment market for several reasons. The region boasts a robust healthcare infrastructure and faces a high prevalence of Prurigo Nodularis cases, which drives demand for effective treatments. Additionally, the presence of major market players, ongoing research and development efforts, and government initiatives to raise awareness about rare skin disorders all contribute to North America's market dominance. Furthermore, the region's stringent regulatory standards ensure the availability of approved and safe treatment options, further solidifying its leading position in the Prurigo Nodularis treatment market.
Leading Prurigo Nodularis Treatment Market Key Players & Competitive Landscape:
The prurigo nodularis treatment market is highly competitive, with several key players vying for market share and actively engaging in strategic initiatives. These companies focus on product innovation, technological advancements, and expanding their product portfolios to gain a competitive edge. These companies are continuously investing in research and development activities to enhance their product offerings and cater to the evolving needs of customers in terms of efficiency, performance, and sustainability.
These companies include:
- Bayer AG
- GlaxoSmithKline plc
- Johnson & Johnson Services Inc
- Merck & Co. Inc
- Pfizer Inc
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
Recent Key Developments:
- In February 2024, Galderma announced that the FDA had accepted its biologics license application (BLA) for nemolizumab for the treatment of prurigo nodularis
- In February 2024, Rеgеnеron Pharmacеuticals, Inc. and Sanofi havе announced that thе U.S. Food and Drug Administration (FDA) has accepted for Priority Review thе supplemental Biologics Licеnsе Application (sBLA) for Dupixеnt (dupilumab). This application is for a potеntial sixth indication, proposing Dupixеnt as an add on maintenance trеatmеnt for certain adult patients with uncontrolled chronic obstructive pulmonary disеasе (COPD).
Prurigo Nodularis Treatment Market Research Scope:
|
Report Metric |
Report Details |
|
Market size available for the years   |
2021-2023 |
|
Base Year |
2023 |
|
Forecast Period       |
2024-2032 |
|
Compound Annual Growth Rate (CAGR) |
3.1% |
|
Segment covered |
Product, distribution channel, and regions. |
|
Regions Covered |
North America: The U.S. & Canada Latin America: Brazil, Mexico, Argentina, & Rest of Latin America Asia Pacific: China, India, Japan, Australia & New Zealand, ASEAN, & Rest of Asia Pacific Europe: Germany, The U.K., France, Spain, Italy, Russia, Poland, BENELUX, NORDIC, & Rest of Europe The Middle East & Africa: Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, and Rest of MEA |
|
Fastest Growing Country in Europe |
Germany |
|
Largest Market |
North America |
|
Key Players |
Bayer AG, GlaxoSmithKline plc, Johnson & Johnson Services Inc, Merck & Co. Inc, Pfizer Inc, Sanofi SA, Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd. |
1. Global Prurigo Nodularis Treatment Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global Prurigo Nodularis Treatment Market Overview
2.1. Introduction
2.1.1. Introduction
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global Prurigo Nodularis Treatment Market Snapshot
2.4. Global Prurigo Nodularis Treatment Market Size and Forecast, 2020–2028
2.4.1. Introduction
2.4.2. Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)
2.5. Global Prurigo Nodularis Treatment Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Key Regulations
2.7. Porter’s Five Forces Model
3. Global Prurigo Nodularis Treatment Market, By Product
3.1. Introduction
3.1.1. Annual Growth Rate Comparison, By Product
3.1.2. BPS Analysis, By Product
3.2. Market Revenue (US$Mn) Forecast, By Product
3.2.1. Antihistamines
3.2.2. Capsacin Cream
3.2.3. Corticosteroids
3.2.4. Emollients
3.2.5. Others
3.3. Global Prurigo Nodularis Treatment Market Attractiveness Index, By Product
4. Global Prurigo Nodularis Treatment Market, By Distribution Channel
4.1. Introduction
4.1.1. Annual Growth Rate Comparison, By Distribution Channel
4.1.2. BPS Analysis, By Distribution Channel
4.2. Market Revenue (US$Mn) Forecast, By Distribution Channel
4.2.1. Retail Pharmacies
4.2.2. Hospital Pharmacies
4.2.3. Online Pharmacies
4.3. Global Prurigo Nodularis Treatment Market Attractiveness Index, By Distribution Channel
5. Global Prurigo Nodularis Treatment Market, By Region
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By Region
5.1.2. BPS Analysis, By Region
5.2. Market Revenue (US$Mn) Forecast, By Region
5.2.1. North America
5.2.2. Latin America
5.2.3. Europe
5.2.4. Asia Pacific
5.2.5. Middle East
5.2.6. Africa
5.3. Global Prurigo Nodularis Treatment Market Attractiveness Index, By Region
6. North America Prurigo Nodularis Treatment Market Analysis and Forecast, 2020–2028
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By Country
6.1.2. BPS Analysis, By Country
6.2. Market Revenue (US$Mn) Forecast, By Country
6.2.1. U.S. Prurigo Nodularis Treatment Market
6.2.2. Canada Prurigo Nodularis Treatment Market
6.3. North America Prurigo Nodularis Treatment Market, By Product
6.3.1. Antihistamines
6.3.2. Capsaicin Cream
6.3.3. Corticosteroids
6.3.4. Emollients
6.3.5. Others
6.4. North America Prurigo Nodularis Treatment Market, By Distribution Channel
6.4.1. Retail Pharmacies
6.4.2. Hospital Pharmacies
6.4.3. Online Pharmacies
6.5. North America Prurigo Nodularis Treatment Market Attractiveness Index
6.5.1. By Country
6.5.2. By Distribution Channel
6.5.3. By Product
7. Latin America Prurigo Nodularis Treatment Market Analysis and Forecast, 2020–2028
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By Country
7.1.2. BPS Analysis, By Country
7.2. Market (US$Mn) Forecast, By Country
7.2.1. Brazil Prurigo Nodularis Treatment Market
7.2.2. Mexico Prurigo Nodularis Treatment Market
7.2.3. Argentina Prurigo Nodularis Treatment Market
7.2.4. Rest Of Latin America Prurigo Nodularis Treatment Market
7.3. Latin America Prurigo Nodularis Treatment Market, By Product
7.3.1. Antihistamines
7.3.2. Capsaicin Cream
7.3.3. Corticosteroids
7.3.4. Emollients
7.3.5. Others
7.4. Latin America Prurigo Nodularis Treatment Market, By Distribution Channel
7.4.1. Retail Pharmacies
7.4.2. Hospital Pharmacies
7.4.3. Online Pharmacies
7.5. Latin America Prurigo Nodularis Treatment Market Attractiveness Index
7.5.1. By Country
7.5.2. By Distribution Channel
7.5.3. By Product
8. Europe Prurigo Nodularis Treatment Market Analysis and Forecast, 2020–2028
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Country
8.1.2. BPS Analysis, By Country
8.2. Market (US$Mn) Forecast, By Country
8.2.1. U.K. Prurigo Nodularis Treatment Market
8.2.2. Germany Prurigo Nodularis Treatment Market
8.2.3. Italy Prurigo Nodularis Treatment Market
8.2.4. France Prurigo Nodularis Treatment Market
8.2.5. Spain Prurigo Nodularis Treatment Market
8.2.6. Russia Prurigo Nodularis Treatment Market
8.2.7. Poland Prurigo Nodularis Treatment Market
8.2.8. BENELUX Prurigo Nodularis Treatment Market
8.2.9. NORDIC Prurigo Nodularis Treatment Market
8.2.10. Rest Of Europe Prurigo Nodularis Treatment Market
8.3. Europe Prurigo Nodularis Treatment Market, By Product
8.3.1. Antihistamines
8.3.2. Capsaicin Cream
8.3.3. Corticosteroids
8.3.4. Emollients
8.3.5. Others
8.4. Europe Prurigo Nodularis Treatment Market, By Distribution Channel
8.4.1. Retail Pharmacies
8.4.2. Hospital Pharmacies
8.4.3. Online Pharmacies
8.5. Europe Prurigo Nodularis Treatment Market Attractiveness Index
8.5.1. By Country
8.5.2. By Distribution Channel
8.5.3. By Product
9. Asia Pacific Prurigo Nodularis Treatment Market Analysis and Forecast, 2020–2028
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Country
9.1.2. BPS Analysis, By Country
9.2. Market (US$Mn) Forecast, By Country
9.2.1. China Prurigo Nodularis Treatment Market
9.2.2. India Prurigo Nodularis Treatment Market
9.2.3. Japan Prurigo Nodularis Treatment Market
9.2.4. Australia And New Zealand Prurigo Nodularis Treatment Market
9.2.5. South Korea Prurigo Nodularis Treatment Market
9.2.6. ASEAN Prurigo Nodularis Treatment Market
9.2.7. Rest Of Asia Pacific Prurigo Nodularis Treatment Market
9.3. Asia Pacific Prurigo Nodularis Treatment Market, By Product
9.3.1. Antihistamines
9.3.2. Capsaicin Cream
9.3.3. Corticosteroids
9.3.4. Emollients
9.3.5. Others
9.4. Asia Pacific Prurigo Nodularis Treatment Market, By Distribution Channel
9.4.1. Retail Pharmacies
9.4.2. Hospital Pharmacies
9.4.3. Online Pharmacies
9.5. Asia Pacific Prurigo Nodularis Treatment Market Attractiveness Index
9.5.1. By Country
9.5.2. By Distribution Channel
9.5.3. By Product
10. Middle East Prurigo Nodularis Treatment Market, By Region
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Country
10.1.2. BPS Analysis, By Country
10.2. Market (US$Mn) Forecast, By Country
10.2.1. GCC Countries Prurigo Nodularis Treatment Market
10.2.2. Israel Prurigo Nodularis Treatment Market
10.2.3. Oman Prurigo Nodularis Treatment Market
10.2.4. Rest Of Middle East Prurigo Nodularis Treatment Market
10.3. Middle East Prurigo Nodularis Treatment Market, By Product
10.3.1. Antihistamines
10.3.2. Capsaicin Cream
10.3.3. Corticosteroids
10.3.4. Emollients
10.3.5. Others
10.4. Middle East Prurigo Nodularis Treatment Market, By Distribution Channel
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacies
10.4.3. Online Pharmacies
10.5. Middle East Prurigo Nodularis Treatment Market Attractiveness Index
10.5.1. By Country
10.5.2. By Distribution Channel
10.5.3. By Product
11. Africa Prurigo Nodularis Treatment Market, By Region
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Country
11.1.2. BPS Analysis, By Country
11.2. Market (Us$Mn) Forecast, By Country
11.2.1. South Africa Prurigo Nodularis Treatment Market
11.2.2. Egypt Prurigo Nodularis Treatment Market
11.2.3. North Africa Prurigo Nodularis Treatment Market
11.2.4. Rest Of Africa Prurigo Nodularis Treatment Market
11.3. Africa Prurigo Nodularis Treatment Market, By Product
11.3.1. Antihistamines
11.3.2. Capsaicin Cream
11.3.3. Corticosteroids
11.3.4. Emollients
11.3.5. Others
11.4. Africa Prurigo Nodularis Treatment Market, By Distribution Channel
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Online Pharmacies
11.5. Africa Prurigo Nodularis Treatment Market Attractiveness Index
11.5.1. By Country
11.5.2. By Distribution Channel
11.5.3. By Product
12. Recommendation
12.1. Market Strategy
13. Competitive Landscape
13.1. Competition Dashboard
13.2. List and Company Overview of Global Key Players
13.3. Company Profiles
13.3.1. Bayer AG
13.3.1.1. Company Overview
13.3.1.2. Financial Overview
13.3.1.3. Product Portfolio
13.3.1.4. Key Developments
13.3.1.5. Business Strategies
13.3.2. GlaxoSmithKline plc
13.3.3. Johnson & Johnson Services Inc.
13.3.4. Merck & Co. Inc.
13.3.5. Pfizer Inc.
13.3.6. Sanofi SA
13.3.7. Takeda Pharmaceutical Company Limited
13.3.8. Teva Pharmaceutical Industries Ltd.
14. Acronyms
Frequently Asked Question
At what CAGR will the prurigo nodularis treatment market expand?
The market is anticipated to rise at 3.1% through 2032.
What are some key factors driving revenue growth of the prurigo nodularis treatment market?
Some key factors driving prurigo nodularis treatment market revenue growth includes advancements in treatment, increasing healthcare expenditure, strategic partnerships and collaborations and expansion in emerging markets.
What are some major challenges faced by companies in the prurigo nodularis treatment market?
Companies face challenges such as limited treatment options, clinical trial design, regulatory hurdles, patient recruitment and retention and access and reimbursement.
How is the competitive landscape in the prurigo nodularis treatment market?
The market is competitive, with key players focusing on technological advancements, product innovation, and strategic partnerships. Factors such as product quality, reliability, after-sales services, and customization capabilities play a significant role in determining competitiveness.
What is the best treatment for nodular prurigo?
The best treatment for noular prurigo is the use of topical or intralesional steroids.
Is nodular Prurigo curable?
There is no cure for prurigo curable.
Is nodular prurigo cancerous?
It can appear on its own or be associated with cancer or one of the many other diseases it has been linked to
Who are the leading key players in prurigo nodularis treatment market?
The leading key players in the prurigo nodularis treatment market are Bayer AG, GlaxoSmithKline plc, Johnson & Johnson Services Inc, Merck & Co. Inc, Pfizer Inc, Sanofi SA, Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.